Pre-market hot trades in US stocks: Novo Nordisk AS pre-market down 7.52%; Amaze pre-market down 5.50%

Pre-market Hot Trades in US Stocks

Novo Nordisk pre-market down 7.52%. Based on recent key news:

1. On July 28, India approved Novo Nordisk's weight loss drug Wegovy for the treatment of fatty liver disease. Although this move may expand the market, it faces fierce competition. There are more efficient but higher-priced Eli Lilly drugs in the Indian market, as well as cheaper generic drugs, putting pressure on Novo Nordisk's stock price;

2. On July 29, investors accused Novo Nordisk of misleading the market during the CagriSema clinical trial, leading to a significant drop in stock price. Investors claimed the company made false statements regarding the trial results' tolerability, affecting market confidence;

3. On July 29, the legal dispute between Novo Nordisk and Eli Lilly intensified, involving unfair competition in advertising. Novo Nordisk accused Eli Lilly of improper advertising, affecting its market performance. The competition in the pharmaceutical industry has intensified, and market volatility is evident.

Amaze pre-market down 5.50%. Based on recent key news:

1. On July 27, Amaze Holdings released positive news about its revenue ecosystem. The company stated that early subscription acceptance has increased, demand for Amaze Affiliates has risen, and ongoing testing of Amaze Media indicates that revenue opportunities on the platform are expanding. This news boosted market confidence in the company's future growth, but the stock price still fell.

2. On July 27, the company announced the development of new infrastructure to facilitate connections between brands and creators, significantly increasing the scope of affiliate marketing activities. This initiative aims to streamline processes and enhance creators' earning opportunities, expected to revolutionize affiliate marketing. However, the market's reaction to this news was not as expected, leading to a decline in stock price.

3. On July 27, the company's forward-looking statements mentioned that despite positive market developments, risks and uncertainties still exist. The company emphasized that these forward-looking statements only represent estimates and assumptions as of the release date, and the market's cautious attitude towards these statements may lead to stock price volatility. The market reacted cautiously to the forward-looking statements, resulting in stock price fluctuations.

Top Gainers in Pre-market US Stocks

Microbus pre-market up 220%. Based on recent key news:

1. On July 30, Wetour Robotics announced a stock consolidation plan with a consolidation ratio of 1 to 100. This move aims to improve stock liquidity and market attractiveness, expected to take effect on August 3. This news drove the stock price up.

2. On July 29, the SEC issued a statement reminding investors to be cautious regarding forward-looking statements. Such statements may affect market confidence, leading to stock price volatility.

3. On July 29, Fermi and Galaxy Digital faced challenges amid changes in cryptocurrency regulation, with investors' interest in risk assets fluctuating. In this context, signals from the traditional commodity market are mixed, affecting the market performance of related stocks. Changes in cryptocurrency regulation impact market confidence Replimune pre-market up 133.46%. Based on recent key news:

4. On July 31, the FDA external advisory panel supported the trial results of Replimune's RP1 drug, leading to a significant increase in stock price. The drug seeks accelerated approval for the treatment of advanced melanoma, with a final decision expected on August 2. Source: Reuters

5. On July 30, Replimune announced favorable results from the FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting, further boosting market confidence. Source: Reuters

6. On July 28, FDA reviewers expressed concerns about the efficacy of the RP1 drug trial, resulting in a stock price decline. Source: Reuters The biotechnology industry has been volatile recently, requiring attention to policy changes.

Cycurion pre-market up 77.63%. Based on recent key news:

1. On July 31, Cycurion announced it secured a government contract worth $54.6 million, the largest contract in the company's history. This contract is expected to generate over $5 million in revenue annually, with work set to begin in November 2026. This news caused the stock price to soar nearly 400%.

2. On July 30, Cycurion partnered with one of the top five consulting firms globally to win a 10-year contract supporting the modernization and secure operation of state government health and human services systems. This contract is expected to bring in over $5 million in long-term public sector revenue annually.

3. On July 30, analysts expect Cycurion to announce quarterly results on August 13, forecasting a loss of $0.56 per share and revenue of $3.62 million. Despite a year-over-year decline in revenue, analysts remain optimistic about the company's future performance. The cybersecurity industry has performed strongly recently, and government contracts have increased market confidence